Intelligence Feed event · Capital · 2026-09-20

    Electra Therapeutics Sets Terms for $347M Nasdaq IPO

    Question

    Electra Therapeutics Sets Terms for $347M Nasdaq IPO

    Direct answer

    Electra Therapeutics established pricing terms for its Nasdaq initial public offering, planning to issue 21.7 million shares in a range of $14.00 to $16.00 per share under ticker ETRA. The deal would raise up to $347 million at the top end. Capital raised is allocated toward clinical progression of ipsoprubart through the SURPASS registration trial, targeting secondary haemophagocytic lymphohistiocytosis, providing a key benchmark for primary biopharma issuance sentiment.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-20
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Electra Therapeutics Sets Terms for $347M Nasdaq IPO”, revision 1, evidence through 2026-09-20. https://marketontology.com/market-events/2026-09-20/electra-therapeutics-sets-terms-for-347m-nasdaq-ipo-f6e6fa

    CAPITAL
    Electra Therapeutics Sets Terms for $347M Nasdaq IPO
    Electra Therapeutics established pricing terms for its Nasdaq initial public offering, planning to issue 21.7 million shares in a range of $14.00 to $16.00 per share under ticker ETRA. The deal would raise up to $347 million at the top end. Capital raised is allocated toward clinical progression of ipsoprubart through the SURPASS registration trial, targeting secondary haemophagocytic lymphohistiocytosis, providing a key benchmark for primary biopharma issuance sentiment.
    ETRAJEF
    Impact
    68
    SEP 20
    SIG
    88%
    ETRAJEF
    Electra Therapeutics Sets Terms for $347M Nasdaq IPO
    Electra Therapeutics established pricing terms for its Nasdaq initial public offering, planning to issue 21.7 million shares in a range of $14.00 to $16.00 per share under ticker ETRA. The deal would raise up to $347 million at the top end. Capital raised is allocated toward clinical progression of ipsoprubart through the SURPASS registration trial, targeting secondary haemophagocytic lymphohistiocytosis, providing a key benchmark for primary biopharma issuance sentiment.
    → New equity issuance expands clinical trial funding capacity while testing institutional investor risk appetite in the biotech ECM window.
    Impact
    Electra Therapeutics established pricing terms for its Nasdaq initial public offering, planning to issue 21.7 million shares in a range of $14.00 to $16.00 per share under ticker ETRA. The deal would raise up to $347 million at the top end. Capital raised is allocated toward clinical progression of ipsoprubart through the SURPASS registration trial, targeting secondary haemophagocytic lymphohistiocytosis, providing a key benchmark for primary biopharma issuance sentiment.
    Affected
    ETRAJEF
    Transmission
    New equity issuance expands clinical trial funding capacity while testing institutional investor risk appetite in the biotech ECM window.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ETRAprimary market capital issuance and equity valuationWatch1-5dElectra Therapeutics is pricing 21.7M shares at $14-$16 targeting up to $347M.
    JEFECM underwriting fee realizationUp1-4wJefferies listed among offering participants in IPO syndicate.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month